0J7G Hutchison China Meditech Ltd

TIDMHCM

RNS Number : 7882I

Hutchmed (China) Limited

17 August 2021

ELECTRONIC COMMUNICATION

OF CORPORATE INFORMATION

Hong Kong, Shanghai & Florham Park, NJ - August 17, 2021: HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM: HCM; HKEX: 13) announces that it has written to its shareholders regarding its intention to adopt electronic communication methods for shareholder documents, including the annual report ("Corporate Communications").

Reducing the number of communications sent by post should not only result in cost savings but is also consistent with the Company's commitment to protecting the environment by minimizing the use of paper, reducing waste and pollution, cutting printing and mailing costs, and enabling the Company to deliver information to shareholders in a timely, convenient and cost-effective form.

The Company is recommending that shareholders elect to receive the website version of Corporate Communication s . A letter setting out the options available to shareholders, will be sent to shareholders on August 18, 2021. Shareholders wishing to continue to receive shareholder documents in hard copy form will need to notify the Company's UK Registrar by no later than September 17, 2021, by completing and returning the response form included in the letter. If the Company does not receive shareholders' response by September 17, 2021 , such shareholders are deemed to have agreed to receive the website version of Corporate Communication s in stead of printed copies. Shareholders are entitled to change their choice of means of receipt of Corporate Communications at any time by providing reasonable notice to the UK Registrar, Computershare Investor Services Limited, by post, to the Company by email to webcorres@computershare.co.uk or by accessing the UK Registrar's Investor Centre at www.investorcentre.co.uk/ecomms using the SRN provided in the letter to shareholders.

For shareholders who elect to receive Corporate Communication s in printed form, the Company will send such shareholders all Corporate Communication s by mail .

For shareholders who elect, or are deemed to have consented, to receive the website version of Corporate Communication s , the Company will notify such shareholders by email as and when Corporate Communications are posted on the website of the Company. If no email address is provided by shareholders, the Company will notify such shareholders by mail of the posting of Corporate Communications on the website of the Company.

All Corporate Communication s in both English and Chinese in accessible format will be available on the website of the Company at www.hutch-med.com for a period of at least five years.

Further details are set out in the letter, which will shortly be available on the Company's website at www.hutch-med.com.

About HUTCHMED

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,400 personnel has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Important Notice

This announcement is for information purposes only and does constitute or form a part of any offer to sell or solicitation to purchase, acquire or subscribe for securities in Hong Kong, the United States or elsewhere.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or to any U.S. person (as defined in Regulation S under the U.S. Securities Act of 1933, as amended from time to time, (the "U.S. Securities Act") or any other jurisdiction where such distribution is prohibited by law.

This announcement does not constitute an invitation or inducement to enter into investment activity within the meaning of section 21 of the U.K. Financial Services and Markets Act 2000, as amended.

CONTACTS

 
Investor Enquiries 
Mark Lee, Senior Vice President       +852 2121 8200 
Annie Cheng, Vice President           +1 (973) 567 3786 
 
Media Enquiries 
Americas - Brad Miles,                +1 (917) 570 7340 (Mobile) 
 Solebury Trout                        bmiles@troutgroup.com 
Europe - Ben Atwell / Alex Shaw,      +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) 
 FTI Consulting                        HUTCHMED@fticonsulting.com 
Asia - Zhou Yi,                       +852 97 83 6894 (Mobile) 
 Brunswick                             HUTCHMED@brunswickgroup.com 
 
Nominated Advisor 
  Atholl Tweedie / Freddy Crossley, 
   Panmure Gordon (UK) Limited        +44 (20) 7886 2500 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCZZGMRZVZGMZM

(END) Dow Jones Newswires

August 17, 2021 04:30 ET (08:30 GMT)

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025

Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025